INGN
Inogen, Inc.
INGN trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over INGN overall, supported by stronger fundamentals and stronger modeled upside.
INGN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
INGN's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INGN PE Valuation
INGN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect INGN's losses to shrink, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over INGN on the outlook, with more favorable revenue expectations.
INGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.31 | -$0.30 |
| Q2 2026 | -$0.90 | +$0.16 |
| Q1 2026 | -$0.91 | +$0.24 |
| Q4 2025 | -$0.86 | +$0.66 |
| Q3 2025 | -$1.01 | +$1.25 |
| Q2 2025 | -$1.06 | +$2.92 |
| Q1 2025 | -$1.15 | +$3.01 |
| Q4 2024 | -$1.52 | +$2.90 |
INGN is still losing money, but far less than before: $1.31 per share over the past year, against $5.75 at its worst in late 2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over INGN on earnings quality, reporting a profit while its opponent remains loss making.
INGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $77.2M | -16% |
| Q2 2026 | $95.1M | +3% |
| Q1 2026 | $85.1M | +3.4% |
| Q4 2025 | $81.7M | +2% |
| Q3 2025 | $92.4M | +4% |
| Q2 2025 | $92.3M | +4% |
| Q1 2025 | $82.3M | +5.5% |
| Q4 2024 | $80.1M | +5.5% |
INGN's revenue fell from its 2022 peak and has held roughly level since: $77M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -13 points |
| Q2 2026 | -5.4% | +1.3 points |
| Q1 2026 | -11% | -1.7 points |
| Q4 2025 | -11% | +2.8 points |
| Q3 2025 | -7.7% | +1.1 points |
| Q2 2025 | -6.6% | +1.3 points |
| Q1 2025 | -9.3% | +12 points |
| Q4 2024 | -14% | +24 points |
INGN's operating margin was −20% last quarter, down 12 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over INGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over INGN on profitability, with a higher operating margin.
INGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.8M | -397% |
| Q2 2026 | $2.2M | -39% |
| Q1 2026 | -$6.9M | +$10.2M |
| Q4 2025 | -$1.9M | +$1.4M |
| Q3 2025 | $1.6M | -70% |
| Q2 2025 | $3.7M | -45% |
| Q1 2025 | -$17.1M | -$11M |
| Q4 2024 | -$3.3M | +$1.2M |
INGN's free cash flow was −$11M over the past year, against −$15M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over INGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
INGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.2% | -584K shares |
| 1 year | -2.3% | -614K shares |
| 3 years | +14% | +3.2M shares |
| 5 years | +16% | +3.6M shares |
| Available history | +21% | +4.6M shares |
INGN has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.7M |
| Q2 2026 | $5.6M |
| Q1 2026 | $1.9M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -122.1x | Net Cash |
| Q1 2022 | -13.6x | Net Cash |
| Q4 2021 | -8.9x | Net Cash |
| Q3 2021 | -9.0x | Net Cash |
| Q2 2021 | -13.6x | Net Cash |
| Q1 2021 | -80.5x | Net Cash |
| Q4 2020 | -103.4x | Net Cash |
| Q3 2020 | -110.1x | Net Cash |
INGN has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.4 | Neutral |
| Stochastic | 47.7 | Neutral |
INGN's weekly RSI is 43 (neutral) and its Stochastic is 48 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INGN PE vs Healthcare Sector
| Metric | INGN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INGN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.17 | 8.9% below |
| 20 week MA | $6.02 | 6.6% below |
| 50 week MA | $6.28 | 11% below |
| 100 week MA | $7.07 | 21% below |
| 200 week MA | $8.28 | 32% below |
INGN is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over INGN on trend strength, trading above more of its moving averages.
INGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.5 | $43.3 | -37% |
| 2021 | $43.3 | $32.7 | -25% |
| 2022 | $32.7 | $19.9 | -39% |
| 2023 | $19.9 | $5.49 | -72% |
| 2024 | $5.49 | $8.58 | +56% |
| 2025 | $8.58 | $6.80 | -21% |
| 2026 YTD | $6.80 | $5.62 | -17% |
INGN has finished lower in five of the last six years. It's down 17% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over INGN on returns for 2026, with the stronger performance.